Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
about
Cannabinoids in health and diseasePositive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporterThe endocannabinoid system as an emerging target of pharmacotherapyEndocannabinoid system: emerging role from neurodevelopment to neurodegeneration.Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity.In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liabilityInhibition of striatal dopamine release by CB1 receptor activation requires nonsynaptic communication involving GABA, H2O2, and KATP channelsNeurochemical and electrophysiological characteristics of rat striatal neurons in primary culture.Quantification of brain endocannabinoid levels: methods, interpretations and pitfallsThe endocannabinoid system as a target for the treatment of neurodegenerative disease.Psychopharmacology of the endocannabinoids: far beyond anandamide.The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ anAnandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172.Transcriptome analysis in a rat model of L-DOPA-induced dyskinesiaThe CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned ratsExperimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotectionEndocannabinoid signaling in midbrain dopamine neurons: more than physiology?Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's diseaseCannabinoid CB1 and Dopamine D1 Receptors Partnership in the Modulation of Emotional Neural Processing.Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotectionThe cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated ratsDopamine-dependent corticostriatal synaptic filtering regulates sensorimotor behavior.New insights on endocannabinoid transmission in psychomotor disorders.Novel pharmacological strategies for motor complications in Parkinson's disease.Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.Brain 2-Arachidonoylglycerol Levels Are Dramatically and Rapidly Increased Under Acute Ischemia-Injury Which Is Prevented by Microwave Irradiation.The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of actionNeurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2Targeting the endocannabinoid system: to enhance or reduce?Endocannabinoid signaling in microglial cellsMarijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.Cocaine-induced endocannabinoid release modulates behavioral and neurochemical sensitization in miceThe Ratio of 2-AG to Its Isomer 1-AG as an Intrinsic Fine Tuning Mechanism of CB1 Receptor Activation.Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.Endocannabinoid modulation of dopaminergic motor circuits.Dyskinesias in Parkinson's disease: views from positron emission tomography studies.The endocannabinoid system: a putative role in neurodegenerative diseases.The role of cannabinoids and leptin in neurological diseases.
P2860
Q24633884-67211500-6147-49F2-8081-D56AA3E702E6Q24644993-60D1F186-1B8D-4FCA-8FCD-6D68BA4A808CQ24648473-ED190681-4CE5-4F3E-93C1-FC6F51F726AAQ30391852-871EAD6F-1D43-4639-B739-3B1B2AC3D08EQ30493991-2869999D-12F9-4094-A778-0D01F0B90882Q33751118-8C6F4012-5EFE-41A3-842D-B22A55688FB4Q33996977-FBA16A1E-0D19-4500-8CE6-1C84553D8494Q34071218-5E8D7685-5813-4E1E-91F7-4E2B0093E6E7Q34098167-61088A7A-8384-4DD3-93ED-44C90306B0CFQ34098196-519BDD49-85FC-4E11-A076-836812A0475AQ34190754-A43302C0-D3AF-4E2A-9DCA-514E9EB42468Q34267133-311267F1-740F-420D-8AC7-A8544FA001F6Q34320147-F54B3217-E1E5-4A8C-A9C4-799A3CD5EAD1Q34400095-72499A2C-F005-447C-B208-A7889EB5E9DFQ34482483-3BFCEC02-CE6C-4F2D-8006-B3412D15728DQ34597537-28AF2F72-E322-4735-9ACF-6D976E0F571FQ34967151-EB3AE072-4E1B-4D0E-9955-CA65821E21AFQ35070472-069CED37-B5FC-462D-9888-17DE2194F3EBQ35193305-CE3DBB4A-F90F-47A3-9595-DD08BFF0058AQ35333369-71041FEE-F21B-4801-B009-EF9D5A362A4AQ35499568-30BD1E2D-635D-4093-9833-43C91786BF5DQ35740152-1CEC9219-B3F1-4C03-BBC4-A2808531F3D9Q35828317-16E0CB63-0DA9-4ABF-A50F-71AD906E25B3Q36074595-402BA770-E398-4EBF-8AA0-3F745A38A528Q36120761-22901D5E-FFE3-4DAD-AB0C-8CE277F5716CQ36248857-65F81167-ACE9-4EF2-A90A-5A964FFD683BQ36341688-FFAED2C9-4811-4504-977F-F790155A043EQ36759329-6FFD829C-5FE5-4F73-ADDF-B10B962B9556Q36943243-B67A48BF-387A-4AF9-A5CA-0DAC07F266FAQ37132571-EA7CFEC2-3215-437B-8617-39D894269F04Q37150745-590ED24F-2C4B-4926-AC37-360EBEF478E0Q37250243-C7A98014-6040-4017-BE7B-494CE3612F33Q37512670-4D54EF47-DA9F-4755-A504-72AEC124C3A1Q37554546-9AD21ECE-BA30-4EB9-B9A4-7D6853D09928Q37651666-F08F944D-A3DE-410F-AD8F-0C71F1D97E01Q37924629-B4ADC075-F330-45C9-B84C-AC6EAF8DAF11Q38018946-22CAB1E6-B600-4765-9478-0C00AA262108Q38182651-3EB262FA-6DBA-4872-8A71-C75006E103E2Q38223774-D4BB6B54-2BBF-4A5C-9ACC-DB70E012FEF8Q38423817-6313C128-6AC2-4314-B5F6-98C8BE9064C9
P2860
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Effects of levodopa on endocan ...... levodopa-induced dyskinesias.
@en
Effects of levodopa on endocan ...... levodopa-induced dyskinesias.
@nl
type
label
Effects of levodopa on endocan ...... levodopa-induced dyskinesias.
@en
Effects of levodopa on endocan ...... levodopa-induced dyskinesias.
@nl
prefLabel
Effects of levodopa on endocan ...... levodopa-induced dyskinesias.
@en
Effects of levodopa on endocan ...... levodopa-induced dyskinesias.
@nl
P2093
P2860
P921
P1476
Effects of levodopa on endocan ...... levodopa-induced dyskinesias.
@en
P2093
Andrea Giuffrida
Belen Ferrer
Daniele Piomelli
Nick Asbrock
Satish Kathuria
P2860
P304
P356
10.1046/J.1460-9568.2003.02896.X
P407
P577
2003-09-01T00:00:00Z